Cyclic Peptide IL-1β Trap for Cardiovascular Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis primarily focus on cholesterol-lowering medications, which while effective, do not adequately address the inflammatory component of the disease, particularly the role of interleukin-1β (IL-1β) in vascular inflammation.
Innovation Solution
Development of cyclic peptides that specifically bind to IL-1β, preventing its engagement with the IL-1 receptor and thereby inhibiting downstream pro-inflammatory signaling, offering a novel therapeutic approach for treating cardiovascular diseases associated with inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cholesterol-lowering medications are used to treat atherosclerosis, then the buildup of fatty acid deposits is reduced and arterial health is improved, but the inflammatory component of the disease, particularly IL-1β mediated vascular inflammation, is not adequately addressed
Solution Approach 1:
The treatment approach is segmented into two distinct therapeutic targets: cholesterol metabolism (addressed by statins and other lipid-lowering agents) and inflammation (addressed by the cyclic peptide IL-1β trap). This segmentation allows each medication class to optimize its specific function while the combination provides comprehensive coverage of both major atherosclerosis pathways.
Solution Approach 2:
The cyclic peptide compound provides multi-functionality by simultaneously targeting IL-1β cytokine activity, thereby addressing both the inflammatory and cardiovascular aspects of atherosclerosis. This universal approach enables a single agent to contribute to multiple therapeutic outcomes: reducing vascular inflammation, preventing plaque progression, and potentially stabilizing existing plaques.
2Reliability
If canakinumab (IL-1β monoclonal antibody) is used to reduce vascular inflammation, then cardiovascular events are reduced, but the treatment is not orally administered and may have limited accessibility
Solution Approach 1:
The patent replaces the injectable monoclonal antibody mechanism with an oral small molecule cyclic peptide. This substitution changes the administration route from parenteral (injection) to oral, significantly improving ease of operation and patient compliance while maintaining the core function of IL-1β inhibition through a different molecular mechanism.
Solution Approach 2:
The invention changes critical parameters of the therapeutic agent: molecular size, chemical structure, and administration route. By transforming the large protein-based canakinumab into a smaller cyclic peptide with specific molecular weight and structural properties, the compound becomes suitable for oral administration while retaining IL-1β binding capability and therapeutic efficacy.
3Adaptability or versatility
If additional anti-inflammatory therapies are added to cholesterol-lowering medications, then comprehensive treatment of atherosclerosis is achieved, but treatment complexity and cost increase
Solution Approach 1:
The patent extracts the anti-inflammatory function from the complex landscape of available medications by identifying and targeting the specific IL-1β cytokine pathway. This extraction allows for a focused therapeutic approach that addresses inflammation without requiring multiple concurrent medications, thereby simplifying the overall treatment regimen while maintaining comprehensive coverage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic peptides effectively trap IL-1β, reducing inflammation and potentially offering a complementary or additive treatment to existing cholesterol-lowering therapies for managing atherosclerosis and related cardiovascular conditions.
Implementation Method 1
cyclic peptides that specifically bind to IL-1β, preventing its engagement with the IL-1 receptor
Data Source
AI summary
Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, R1-R9, RA, RB, RD, A1, A2, and subscripts t and w are as herein described.The compounds and their pharmaceutically acceptable salts can trap IL-1β and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.